Journal Articles on Mesothelioma: October, 2006
October 17th, 2006. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells
Conclusions: The current results suggested that constitutive expression of EphA2 may contribute to the aggressive behavior and cellular survival of MMCs. EphA2 may be an effective therapeutic target in patients with mesothelioma. Silencing the receptor EphA2 gene is a novel approach for the containment of growth and migration of tumor in patients with malignant mesothelioma. Cancer 2006. © 2006 American Cancer Society.
October 14th, 2006. Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells
After IP or IN administration, APMS were non-immunogenic and non-toxic as evaluated by differential cell counts and lactate dehydrogenase (LDH) levels in bronchoalveolar and pleural lavage fluids (BALF, PLF). In the treatment of lung and pleural diseases, APMS-TEG may be useful tools to deliver chemotherapeutic drugs or molecular constructs.
October 13th, 2006. Epidemiology of peritoneal mesothelioma: a review
The role of other suspected risk factors, such as simian virus 40 infection and genetic predisposition, is unclear at present. Control of asbestos exposure remains the main approach to prevent peritoneal mesothelioma.
October 13th, 2006. Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases
Conclusions: The morbidity and mortality results for cytoreductive surgery and perioperative intraperitoneal chemotherapy for patients with DMPM were within the acceptable range for major gastrointestinal surgery. Grade IV morbidity was associated with more extensive cytoreduction.
Posted in Determining Efficacy, Diffuse mesothelioma, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 13th, 2006. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma
Conclusions: This series confirms the reproducibility of the trimodality treatment for MPM,which is associated with prolonged survival for early-stage tumors at the cost of a not prohibitive treatment-related mortality rate.
October 10th, 2006. Aurora kinase inhibitors: a new class of targeted drugs in cancer
Phase II trials are under way in selected tumor types. This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents.
October 7th, 2006. Sarcomatous pleural mesothelioma metastatic to left ventricular endocardium
Abstract A 71-year-old man, a cigarette smoker with long-term asbestos exposure, developed multifocal malignant sarcomatous pleural mesothelioma that metastasized to the left ventricular endocardium without invading pericardium, myocardium, or the contiguous pulmonary vein. This is the first reported case of malignant pleural mesothelioma to metastasize in such a manner.
October 5th, 2006. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma
Our results suggest that PPM is an angiogenesis-dependent neoplasia. Therefore, antiangiogenic compounds should be tested particularly in those patients with highly vascularized PPM.
October 5th, 2006. The contribution of occupational risks to the global burden of disease: summary and next steps
Conclusions: These global and regional analyses have identified areas where specific preventive actions are required.
October 5th, 2006. The scientific basis of a total asbestos ban
The role of SV40 as yet is unclear: even assuming that current risk estimates are correct (which is debatable), this agent would interact with asbestos in only a faction of mesothelioma cases. The effectiveness of protocols suggested for "controlled use" has not been tested with a scientfiic approach: they seem hardly practicable, particularly in the countries which are currently the major consumers of asbestos.
October 5th, 2006. Lung cancer in a female non-smoker with occupational exposure to asbestos: a case report
Conclusions: We concluded that a six-year exposure to high doses of asbestos may induce lung cancer and asbestosis in a female non-smoker.
October 3rd, 2006. Pleural mesothelioma in cotton spinning workers
Conclusion: The results of this investigation indicate the attribution, at least, of possible asbestos exposure for those cases employed in textile industries since the fifties, according to the Re.Na.M guidelines; for those cases employed before that period the same classification can be attributed on an epidemiological basis. Previous work periods need further investigation in order to demonstrate the circumstances of the occupational asbestos exposure, given the heterogeneity of work processes and machinery characteristic of this industrial sector.
October 3rd, 2006. Diagnosis of asbestos-related pleuropolmonary diseases
As regards the pleural plaques and asbestos bodies we remark that they are merely exposition markers. We also discussed the problems the pathologist may encounter in diagnosing mesothelioma; in this field the prospects are encouraging as microarray analysis are beginning to identify new molecular markers for mesothelioma.
October 3rd, 2006. National epidemiologic surveillance systems of asbestos-related disease and the exposed workers register
Conclusions: A national, coordinated and uniform epidemiological surveillance system of cases of mesothelioma and the definition of asbestos exposure through active research is extremely important in identifying unexpected contaminating sources. The register of asbestos-exposed workers allows risk to be monitored and protection measures to be implemented.
October 3rd, 2006. Extrapleural pneumonectomy in children
Conclusions: EPP can be performed with curative intent in selected pediatric patients with pleural-based malignancies. EPP should be included in the armamentarium of the pediatric thoracic surgeon and evaluated in larger studies.
October 3rd, 2006. Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approaches
Conclusion: The Pinnacle and Corvus dose calculations were acceptable for thoracic IMRT in high-dose regions. Beam modeling is likely the most critical factor for the accuracy of IMRT dose calculations.
October 3rd, 2006. Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy
Conclusions: Despite early toxicity, CS plus HIPC may prolong the overall survival rate of patients with peritoneal metastases and improve quality of life measurements.
|
|  |
